Medication info
Truempajeong 25 mg (Empagliflozin)

Truempajeong 25 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Boryung Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
For domestic use - 30 tablets/PTP [(10 tablets/PTP × 3)]
Approval status
Active

MFDS item code 202105616 · Approved 2021.07.29 · Insurance code 641908610

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, either as monotherapy or as add-on therapy with other glucose-lowering agents, such as insulin. If 10 mg once daily is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment is not recommended in patients aged 85 years or older because clinical experience in this age group is limited (see Precautions for Use, section 4, General Precautions).

Ingredients

Manufacturer
Boryung Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with difficult blood sugar control
  • cardiovascular disease
View approved original text

This medication is used to help improve blood sugar control in patients with type 2 diabetes mellitus. It can be administered as an adjunct to dietary and exercise therapy and is effective either alone or in combination with other medications. Caution is needed when administered to patients with cardiovascular diseases who have insufficient blood sugar control. Please consult your physician. This medication plays an important role in improving blood sugar control which is essential for diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, either as monotherapy or as add-on therapy with other glucose-lowering agents, such as insulin. If 10 mg once daily is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment is not recommended in patients aged 85 years or older because clinical experience in this age group is limited (see Precautions for Use, section 4, General Precautions).

Precautions

This medication should not be used by those with allergies to the active ingredient or any of the ingredients. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication should not be used in patients with severely impaired kidney function, that is, a glomerular filtration rate of less than 30 mL/min/1.73m2, or in patients with end-stage kidney disease or those undergoing dialysis. Since this medication contains lactose, patients with genetic issues such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. Patients with mildly impaired kidney function should be monitored closely, and if kidney function drops below a certain level, this medication should be discontinued. In certain stages of heart failure, there may be limited experience with this medication, so it should be used cautiously, especially in severe heart failure patients. When used in conjunction with blood sugar-lowering agents like insulin or sulfonylureas, dose adjustments may be necessary due to the risk of hypoglycemia. During treatment with this medication, side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, dehydration, etc., may occur, so symptoms should be monitored carefully. Particularly, serious metabolic abnormalities such as ketoacidosis may occur, so if symptoms like vomiting, abdominal pain, or difficulty breathing appear, immediate consultation with a healthcare professional is necessary. Elderly patients or those at risk of fluid loss should be cautious of dehydration and hypotension, and may temporarily stop taking this medication if needed. There have been reports of liver damage associated with this medication; therefore, patients with liver function abnormalities should use it with caution. Caution is advised when driving or operating machinery due to the risk of hypoglycemia, particularly when combined with other hypoglycemia-inducing drugs. It is recommended that pregnant or nursing women do not use this medication, and if pregnancy is confirmed, they should discontinue use. This medication is not used in pediatric or adolescent patients, as its safety and efficacy have not been established. While no specific toxic symptoms have been reported in case of overdose, appropriate treatment may be necessary depending on the patient's condition. This medication should be kept out of the reach of children and should not be transferred to other containers.

Side effects

  • Hypoglycemia
  • vulvar vaginitis
  • balanitis
  • other genital infections
  • increased urination
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
Show 15 more
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • decreased fluid volume
  • dehydration
  • hypotension
  • decreased blood volume
  • orthostatic hypotension
  • syncope

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to prevent exposure to air or moisture. The storage temperature should be maintained between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

For domestic use - 30 tablets/PTP [(10 tablets/PTP × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.